Palvella Therapeutics宣布拓展Qtorin™雷帕霉素的开发范围,用于治疗临床意义重大的血管角化瘤——一种罕见的慢性致残性淋巴疾病,目前尚无FDA批准的疗法。
Palvella Therapeutics宣布拓展Qtorin™雷帕霉素的开发范围,用于治疗临床意义重大的血管角化瘤——一种罕见的慢性致残性淋巴疾病,目前尚无FDA批准的疗法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.